A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 02 Feb 2016 Planned End Date changed from 1 Oct 2015 to 1 Feb 2016 as per ClinicalTrials.gov record.
    • 28 Jul 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov
    • 02 Jun 2015 Interim results in 8 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top